Vor Biopharma
Develops licensed telitacicept for autoimmune diseases outside Greater China.
Something off on this page? Send us feedback.
Profile
Develops telitacicept, a BAFF/APRIL-targeting autoimmune therapy licensed from RemeGen for territories outside Greater China. The clinical-stage company reset its business after winding down former cancer programs, and current development centers on a global Phase 3 trial in primary Sjögren’s disease.
Develops telitacicept, a BAFF/APRIL-targeting therapy licensed from RemeGen for autoimmune diseases outside Greater China. A global Phase 3 trial in primary Sjögren’s disease is underway, making telitacicept the center of its post-restructuring clinical program for autoimmune-disease development.
The business was reset after the company wound down its former cell-and-genome-engineering cancer programs. The former platform was discontinued. RemeGen retains rights in mainland China, Hong Kong, Macau, and Taiwan, so development and commercialization outside that territory depend on the license. Operations are based in Boston, while the company’s common stock trades on Nasdaq.
Company facts
Key statistics
Year to date +94.6% · Average volume (30d) 788.2K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | Reiterate | Neutral | $18 | $27 | |
| May 14, 2026 | Wedbush | Reiterate | Neutral | $18 | ||
| Apr 15, 2026 | H.C. Wainwright | Target | $55 | $31 | ||
| Dec 23, 2025 | Robert W. Baird | Target | $64 | $46 | ||
| Oct 29, 2025 | H.C. Wainwright | Target | $3 | $55 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.86 | −$1.16 | −35.4% | — | — | — | +0.94% |
| May 13, 2026Q1 FY26 | −$0.75 | −$0.73 | +2.7% | — | — | — | −5.28% |
| Mar 30, 2026Q4 FY25 | −$1.14 | $44.50 | +4,003.5% | — | — | — | +21.36% |
| Nov 13, 2025Q3 FY25 | −$3.06 | −$3.33 | −8.8% | — | — | — | +2.67% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$28.0K | $0 | |
| Operating income | −$33.3M | −$274.3M | −$28.1M | −$36.0M | −$35.2M | −$47.9M | |
| Net income | −$32.5M | −$1.57B | −$812.7M | $1.72B | −$219.6M | −$62.8M | |
| Diluted EPS | −$5.20 | −$251.20 | −$121.63 | $44.50 | −$510.53 | −$1.16 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $466.1M · Total debt $2.9M · Total assets $481.1M · Shareholders' equity −$200.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 54.19M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Rajeev Shah | 12.94M | 19.90% | 13D | Jul 21, 2026 |
| ForGrowth III PA B.V. | 10.24M | 9.99% | 13D | Dec 23, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 5.08M | 9.90% | 13G | May 15, 2026 |
| Verve Capital Limited | 5.00M | 9.30% | 13G | May 15, 2026 |
| FCPM Iii Services B.V. | 4.12M | 7.60% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 16, 2026 | Ra Capital Management, L.P. | 10 percent owner | −213 | $19.75 |
| Apr 22, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −165,150 | $15.77 |
| Apr 20, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −171,963 | $15.77 |
| Apr 17, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −458,411 | $16.28 |
| Apr 15, 2026 | Ra Capital Management, L.P. | director, 10 percent owner: | −53,644 | $16.01 |
Peers
- argenx (ADR)
Commercialized FcRn therapy in gMG and a Sjögren’s trial
- Johnson & Johnson
FDA-approved FcRn blocker for antibody-positive gMG
- AstraZeneca (ADR)
Commercialized C5 inhibitors for antibody-positive gMG
- Novartis (ADR)
Phase 3 anti-BAFF therapy for primary Sjögren’s disease
- Amgen
Phase 3 CD40L blocker for primary Sjögren’s disease
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vor Biopharma | $22.65 | 0.00% | $1.23B | — | — | — | — |
| argenx (ADR) | $1,023.21 | −0.02% | $63.63B | 37.3 | — | 12.4 | — |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Median | 26.9 | 17.4 | 6.1 | +6.5% |